Cargando…

Expression of the immune checkpoint receptor TIGIT in seminoma

A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinsch, Andrea, Blessin, Niclas C., Simon, Ronald, Kluth, Martina, Fischer, Kristine, Hube-Magg, Claudia, Li, Wenchao, Makrypidi-Fraune, Georgia, Wellge, Björn, Mandelkow, Tim, Debatin, Nicolaus F., Höflmayer, Doris, Lennartz, Maximilian, Sauter, Guido, Izbicki, Jakob R., Minner, Sarah, Büscheck, Franziska, Uhlig, Ria, Dum, David, Krech, Till, Luebke, Andreas M., Wittmer, Corinna, Jacobsen, Frank, Burandt, Eike, Steurer, Stefan, Wilczak, Waldemar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607271/
https://www.ncbi.nlm.nih.gov/pubmed/31423216
http://dx.doi.org/10.3892/ol.2019.10428
_version_ 1783432062052597760
author Hinsch, Andrea
Blessin, Niclas C.
Simon, Ronald
Kluth, Martina
Fischer, Kristine
Hube-Magg, Claudia
Li, Wenchao
Makrypidi-Fraune, Georgia
Wellge, Björn
Mandelkow, Tim
Debatin, Nicolaus F.
Höflmayer, Doris
Lennartz, Maximilian
Sauter, Guido
Izbicki, Jakob R.
Minner, Sarah
Büscheck, Franziska
Uhlig, Ria
Dum, David
Krech, Till
Luebke, Andreas M.
Wittmer, Corinna
Jacobsen, Frank
Burandt, Eike
Steurer, Stefan
Wilczak, Waldemar
author_facet Hinsch, Andrea
Blessin, Niclas C.
Simon, Ronald
Kluth, Martina
Fischer, Kristine
Hube-Magg, Claudia
Li, Wenchao
Makrypidi-Fraune, Georgia
Wellge, Björn
Mandelkow, Tim
Debatin, Nicolaus F.
Höflmayer, Doris
Lennartz, Maximilian
Sauter, Guido
Izbicki, Jakob R.
Minner, Sarah
Büscheck, Franziska
Uhlig, Ria
Dum, David
Krech, Till
Luebke, Andreas M.
Wittmer, Corinna
Jacobsen, Frank
Burandt, Eike
Steurer, Stefan
Wilczak, Waldemar
author_sort Hinsch, Andrea
collection PubMed
description A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3(+) immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT(+) and PD-1(+) lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer.
format Online
Article
Text
id pubmed-6607271
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-66072712019-08-18 Expression of the immune checkpoint receptor TIGIT in seminoma Hinsch, Andrea Blessin, Niclas C. Simon, Ronald Kluth, Martina Fischer, Kristine Hube-Magg, Claudia Li, Wenchao Makrypidi-Fraune, Georgia Wellge, Björn Mandelkow, Tim Debatin, Nicolaus F. Höflmayer, Doris Lennartz, Maximilian Sauter, Guido Izbicki, Jakob R. Minner, Sarah Büscheck, Franziska Uhlig, Ria Dum, David Krech, Till Luebke, Andreas M. Wittmer, Corinna Jacobsen, Frank Burandt, Eike Steurer, Stefan Wilczak, Waldemar Oncol Lett Articles A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3(+) immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT(+) and PD-1(+) lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer. D.A. Spandidos 2019-08 2019-05-31 /pmc/articles/PMC6607271/ /pubmed/31423216 http://dx.doi.org/10.3892/ol.2019.10428 Text en Copyright: © Hinsch et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hinsch, Andrea
Blessin, Niclas C.
Simon, Ronald
Kluth, Martina
Fischer, Kristine
Hube-Magg, Claudia
Li, Wenchao
Makrypidi-Fraune, Georgia
Wellge, Björn
Mandelkow, Tim
Debatin, Nicolaus F.
Höflmayer, Doris
Lennartz, Maximilian
Sauter, Guido
Izbicki, Jakob R.
Minner, Sarah
Büscheck, Franziska
Uhlig, Ria
Dum, David
Krech, Till
Luebke, Andreas M.
Wittmer, Corinna
Jacobsen, Frank
Burandt, Eike
Steurer, Stefan
Wilczak, Waldemar
Expression of the immune checkpoint receptor TIGIT in seminoma
title Expression of the immune checkpoint receptor TIGIT in seminoma
title_full Expression of the immune checkpoint receptor TIGIT in seminoma
title_fullStr Expression of the immune checkpoint receptor TIGIT in seminoma
title_full_unstemmed Expression of the immune checkpoint receptor TIGIT in seminoma
title_short Expression of the immune checkpoint receptor TIGIT in seminoma
title_sort expression of the immune checkpoint receptor tigit in seminoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607271/
https://www.ncbi.nlm.nih.gov/pubmed/31423216
http://dx.doi.org/10.3892/ol.2019.10428
work_keys_str_mv AT hinschandrea expressionoftheimmunecheckpointreceptortigitinseminoma
AT blessinniclasc expressionoftheimmunecheckpointreceptortigitinseminoma
AT simonronald expressionoftheimmunecheckpointreceptortigitinseminoma
AT kluthmartina expressionoftheimmunecheckpointreceptortigitinseminoma
AT fischerkristine expressionoftheimmunecheckpointreceptortigitinseminoma
AT hubemaggclaudia expressionoftheimmunecheckpointreceptortigitinseminoma
AT liwenchao expressionoftheimmunecheckpointreceptortigitinseminoma
AT makrypidifraunegeorgia expressionoftheimmunecheckpointreceptortigitinseminoma
AT wellgebjorn expressionoftheimmunecheckpointreceptortigitinseminoma
AT mandelkowtim expressionoftheimmunecheckpointreceptortigitinseminoma
AT debatinnicolausf expressionoftheimmunecheckpointreceptortigitinseminoma
AT hoflmayerdoris expressionoftheimmunecheckpointreceptortigitinseminoma
AT lennartzmaximilian expressionoftheimmunecheckpointreceptortigitinseminoma
AT sauterguido expressionoftheimmunecheckpointreceptortigitinseminoma
AT izbickijakobr expressionoftheimmunecheckpointreceptortigitinseminoma
AT minnersarah expressionoftheimmunecheckpointreceptortigitinseminoma
AT buscheckfranziska expressionoftheimmunecheckpointreceptortigitinseminoma
AT uhligria expressionoftheimmunecheckpointreceptortigitinseminoma
AT dumdavid expressionoftheimmunecheckpointreceptortigitinseminoma
AT krechtill expressionoftheimmunecheckpointreceptortigitinseminoma
AT luebkeandreasm expressionoftheimmunecheckpointreceptortigitinseminoma
AT wittmercorinna expressionoftheimmunecheckpointreceptortigitinseminoma
AT jacobsenfrank expressionoftheimmunecheckpointreceptortigitinseminoma
AT burandteike expressionoftheimmunecheckpointreceptortigitinseminoma
AT steurerstefan expressionoftheimmunecheckpointreceptortigitinseminoma
AT wilczakwaldemar expressionoftheimmunecheckpointreceptortigitinseminoma